Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Urol. Nov 24, 2014; 3(3): 330-335
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.330
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.330
Metabolic syndrome and lower urinary tract symptoms
Hideaki Ito, Osamu Yokoyama, Department of Urology, Faculty of Medical Science, University of Fukui, Yoshida-gun, Fukui 910-8507, Japan
Author contributions: All authors contributed to the paper.
Correspondence to: Hideaki Ito, MD, PhD, Department of Urology, Faculty of Medical Science, University of Fukui, Matsuoka-Shimoaitsuki, 23-3, Eiheiji-cho, Yoshida-gun, Fukui 910-8507, Japan. uroito@u-fukui.ac.jp
Telephone: +81-07-76613111 Fax: +81-07-768126
Received: May 27, 2014
Revised: June 21, 2014
Accepted: July 25, 2014
Published online: November 24, 2014
Processing time: 175 Days and 22.8 Hours
Revised: June 21, 2014
Accepted: July 25, 2014
Published online: November 24, 2014
Processing time: 175 Days and 22.8 Hours
Core Tip
Core tip: Associations between metabolic syndrome (MetS) and lower urinary tract symptom (LUTS) are noteworthy. MetS treatment may have the potential to prevent LUTS from worsening as well as to prevent the occurrence of new LUTS. Medication for LUTS patients with MetS should not only target the lower urinary tract, but should also be recognized as systemic treatment. Medications which are essentially thought to be unrelated to LUTS treatment may have potential for development as a specific medical treatment for LUTS with MetS.